- Home
- FBIO
as 04-18-2025 1:36pm EST
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BAY HARBOR ISLANDS |
| Market Cap: | 44.0M | IPO Year: | N/A |
| Target Price: | $21.00 | AVG Volume (30 days): | 247.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.33 - $2.89 | Next Earning Date: | 05-14-2025 |
| Revenue: | $57,675,000 | Revenue Growth: | -31.76% |
| Revenue Growth (this year): | 63.2% | Revenue Growth (next year): | 66.70% |
Latest Fortress Biotech Inc. News
FBIO Breaking Stock News: Dive into FBIO Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
This Fortress Biotech Insider Increased Their Holding By 26% Last Year
GlobeNewswire
17 days ago
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
Zacks
18 days ago
Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates
GlobeNewswire
18 days ago
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
22 days ago
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
GlobeNewswire
23 days ago
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
GuruFocus.com
25 days ago
Fortress Biotech Inc (FBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings
GlobeNewswire
a month ago
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Compare FBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FBIO Fortress Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.